Adage Capital Partners Gp, L.L.C. Macrogenics Inc Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $7.58 Million - $13.2 Million	-370,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $7.03 Million - $12.3 Million	370,000 New	370,000 $11.8 Million
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $12.3 Million - $15.8 Million	-500,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $2.6 Million - $14.6 Million	500,000 New	500,000 $14 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.